The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update warning stating that Neo-mercazole (carbimazole) is associated with an increased risk of congenital malformations, and urging women of childbearing potential to use effective contraception during treatment.
Consumers and health professionals are advised that the manufacturing issue that resulted in the limited availability of Neo-Mercazole (carbimazole) 5 mg tablets has been resolved.